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Abstract 
Crohn's disease (CD) is one of main disease entities under the umbrella term chronic inflammatory bowel disease. The 
etiology of CD involves alterations in genetic, microbiological, and immunological factors. This review is devoted to 
the role of the bacterial wall compound muramyl dipeptide (MDP) for the activation of inflammatory pathways 
involved in the pathogenesis of CD. The importance of this molecule is underscored by the fact that 1) MDP, which is 
found in most Gram-negative and -positive bacteria, is able to trigger several immunological responses in the intestinal 
system, and 2) that alterations in several mediators of the MDP response including – but not restricted to – nucleotide 
oligomerization domain 2 (NOD2) are associated with CD. The normalization of MDP signaling is one of several 
important factors that influence the intestinal inflammatory response, a fact which emphasizes the pathogenic 
importance of MDP signaling for the pathogenesis of CD. The important aspects of NOD2 and non-NOD2 mediated 
effects of MDP for the development of CD are highlighted, as well as how alterations in these pathways might translate 
into the development of new therapeutic strategies.   
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Introduction 
The innate immune system is the first line of defense in the intestinal tract, and it possesses a unique feature in 
recognizing microbial components. The pathogens are detected by pattern recognition receptors (PRRs), which 
recognize a wide array of conserved structures of microorganisms, called the pathogen-associated molecular patterns 
(PAMPs). The PRRs sense specific viral and bacterial structures, and subsequently initiate various immunological 
responses. PRRs are located on either the membrane surface, e.g. Toll-like receptors (TLRs), or inside the cytoplasm, 
e.g. NOD-like receptors (NLRs) [1]. 
Muramyl dipeptide (MDP) is an immunoreactive peptide found in the peptidoglycan (PGN) motif which encodes 
“the building blocks” of bacterial cell walls [2]. MDP can activate several immunological signaling pathways, including 
the nucleotide oligomerization domain 2 (NOD2, a NLR member) dependent pathway via specific interaction between 
NOD2 and MDP; resulting in activation of nuclear factor-κB (NF-κB), a ubiquitous transcription factor which induces 
expression of pro-inflammatory cytokines [2]. Multiple studies have linked NOD2 to several severe immunological 
dysfunctions such as graft-versus-host disease [3], enhanced mortality during sepsis [4, 5] , and Crohn’s disease (CD) 
[6, 7], indicating that MDP might play a pathophysiological role in these disorders. The NOD2 gene, which initially was 
identified as NOD1-related gene, was found to have a highly restricted expression in monocytes [8]. The major effects 
of NOD2 in the pathogenesis of CD were later revealed by Hugot et al.[6] and Ogura et al.[7], who identified three 
disease linked polymorphisms in the NOD2 gene. As described below, MDP also affects other PRRs than NOD2.  
 CD is one of the two a main entities of inflammatory bowel disease (IBD), potentially affecting any part of the 
gastrointestinal tract, however, most commonly the terminal ileum or the perianal region [9, 10]. The etiology of IBD is 
still unknown, but considering epidemiological, genetic and immunological data together, IBD has a multifactorial 
etiology in which genetic alternations and environmental factors (i.e. microbial behavior) interact to produce the 
immunological background of the disease [11]. Accordingly, it is becoming increasingly evident that an impaired innate 
immunity plays a crucial role in CD [12].  
In this review, the recent studies on MDP-mediated pathways in the innate immunity of CD are summarized 
covering both NOD2 dependent and NOD2 independent pathways. As described in detail below, MDP signaling is 
impaired on different levels in CD, and animal studies suggest that reversal of these pathways reduces intestinal 
inflammation. Revealing such mechanisms might lead to identification of new potential therapeutic approaches of this 
devastating disorder.   
MDP intracellular delivery 
In most Gram-negative and -positive bacteria the PGN represents a key component of the cell wall with an 
important impact on maintaining the structural integrity of plasma membranes and anchoring cell components such as 
lipoproteins [2]. The pivotal role of PGN in the bacterial pathogenesis is clearly highlighted by the fact, that the most 
frequently used antibiotics are targeting the PGN biosynthesis pathway [13]. MDP is a cleavage product and the 
smallest bioactive motif of PGN that specifically binds to NOD2 and it leads to an activation of NOD2-mediated signal 
pathways and other pathways [14]. In general, the structure of PGN contains a repetition of disaccharides (glycans) 
cross-linked by short chains of amino acids (peptides) to form a lattice surrounding the entire cell. MDP consists of N-
acetylmuramic acid linked to the two amino acids: D-Ala and D-isoGln (or D-Glu) [15]. The structure of MDP is 
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unique in the way that MDP analogues  composed of other amino acid leads to a reduced or inhibited ability to induce a 
biological response, also called “the priming effect” [2, 16].  
There is accumulating evidence suggesting that NOD2 might be a selective bacterial sensor due to the fact that 
N-acetyl MDP, which is found in most bacteria, less efficiently activates NOD2 than N-glycolyl MDP – which is found 
in mycobacteria and related Actinomycetes species [17]. This is of interest since CD has been associated with 
mycobacteria infections [18]. Accordingly, Coulombe et al. showed, that N-glycolyl MDP was more efficacious than N-
acetyl MDP at inducing ovalbumin-specific T cell immunity in a model of adjuvancy. Further, N-glycolyl MDP has 
been found to be more potent than N-acetyl MDP in activating NOD2-mediated RIP2 polyubiquitination, NF-κB, as 
well as c-Jun N-terminal kinase (JNK) [17]. A recent in vivo experiment has supported this finding in a setting where 
intravenously administrated MDP has shown protective antiviral activity in mice exposed for influenza A virus (IAV). 
In this model, N-glycolyl MDP showed more potency than N-acetyl MDP and with a greater antiviral activity against 
IAV [19].  
In both Gram-negative and -positive bacteria, the PGN has to be cleaved during cell growth by autolysis which 
allows attaching/inserting of new material into the existing cell wall. The loss of PGN resulting from this cleavage is 
termed “PGN turnover”. However, these turnover products are normally captured and reutilized by the cell in another 
process named “PGN recycling”, which is typically observed in studies with the Gram‐negative bacteria, e.g. 
Escherichia coli [20].  Whether PGN is also recycled in Gram-positive bacteria is basically unknown.  
A number of studies have focused on identifying the mechanisms by which the extracellular NOD2 ligands reach 
the cytosolic receptor and trigger downstream effector functions (Fig.1). The extracellular MDP can get access to the 
host cytosol through several ways. First, MDP can be taken up by the cell via membrane protein transporters, hPepT1 
[21] and pannexin-1 [22]. Inhibition of these transporters leads to a downregulation of MDP localization from the 
extracellular space to the cytosol [22, 23]. Although hPepT1 is expressed in monocytes and human enterocyte cell lines 
like HT-29 cells, most protocols for stimulating primary cells with MDP relies on artificial permeabilisation of the cell 
membranes with liposome forming reagents like lipofectamine, suggesting that the hPepT1 system might be of limited 
efficiency in human cells [24]. Second, MDP similar to lipopolysaccharide (LPS) may use a clathrin- and dynamin-
dependent endocytic pathway to cross the host cell membrane [25-27]. Clathrin and dynamin mediate a vesicle 
formation at the cell membrane, and an inhibition of clathrin or dynamin also leads to attenuated MDP-mediated 
signaling pathways [25]. The mechanism by which MDP is targeted to clathrin-coated pits for endocytosis remains 
unclear. Typically, endocytosis is thought to rely on adaptor transmembrane proteins, such as adaptor protein 2 (AP2), 
to mediate the recruiting process to coated pits by interaction to clathrin adaptors [28]. Third, it has been shown that 
phagocytic cells, interacting with the epithelium breaching microorganisms and microbial components, presents a key 
mechanism in allowing components of microorganisms to be exposed to intracellular receptors: Macrophages may 
generate such microbial components by ingesting whole bacteria and subsequently digesting them in the 
phagolysosomes [29, 30]. Thus, Herskovits et al. [29] have shown that NOD2 is activated in stimulated macrophages by 
bacterial ligands generated in the phagosome and transported to the cytosol [29]. Finally, PGN containing MDP can be 
delivered into the cytosol by the previously mentioned intracellular PGN turnover after internalization of invasive 
bacteria into the cells [31]. 
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MDP-NOD2-mediated pathway  
The NOD2 protein is located in the cytosol and is broadly expressed in macrophages, dendritic cells, and to a lower 
degree in intestinal epithelial cells (IECs), including Paneth cells of the small bowel [32]. The structure of NOD2 
consists of two N-terminal caspase recruitment domains (CARDs), a centrally located nucleotide-binding domain 
(NBD), a C-terminal of site of ligand binding (e.g. MDP), and a leucine-rich repeat region (LRR) (Fig. 2) [8]. MDP 
binds to the LRR of NOD2, which subsequently activates NF-κB and mitogen-activated protein kinases (MAPKs) [33]. 
When activated, NF-κB translocates into the nucleus to initiate cell specific genetic programs, such as immune 
activation, inflammation, and cell development [34, 35]. Recent studies showed that the intestinal MDP-NOD2 pathway 
is tightly controlled by epithelium-associated lymphocytes, which specifically cleave the NOD2-detected MDP 
structure [36, 37]. Pro-inflammatory mediators produced by T helper 1 (Th1) cells, i.e. interferon-γ (IFN-γ) and tumor 
necrosis factor-α (TNF-α), upregulate the expression of NOD2 in intestinal epithelial cells [38]. This reflects the 
importance of NOD2 in the maintenance of the intestinal mucosal homeostasis, which actually links the innate and 
adaptive immunity.  
The specificity of interaction between MDP and NOD2 is not completely understood. However, a recent study 
found that MDP binds directly to NOD2 with high affinity at a pH range of 5.0 to 6.5, compared with a pH range of 7.0 
to 7.5 [39] which is the estimation of human cytosolic pH [40]. pH-dependent affinity of MDP-NOD2 interaction lines 
with earlier observations suggested that the internalization of MDP is optimal in the pH range from 5.5 to 6.5 [26]. 
MDP binding onto NOD2 causes a conformational change allowing a CARD-CARD interaction between NOD2 and 
RIP2 (receptor-interacting protein 2), a CARD-containing serine-threonine [41, 42]. The activation of RIP2 results in 
polyubiquitination of NEMO (NF-κB essential modifier), also named IKKγ (inhibitor of IκB kinase γ), which is found 
in complex with IKKα and IKKβ [43, 44]. IKKγ polyubiquitylation leads to phosphorylation of IKKβ, which in turn 
phosphorylates IκB (inhibitor of NF-κB) resulting in dissociation of IκB from NF-κB. Subsequently NF-κB can 
translocate into the nucleus where it promotes transcription of several pro-inflammatory and anti-inflammatory 
cytokines, such as interleukin-1 (IL-1), IL-2, IL-6, IL-8, IL-12, and TNF-α [32, 33, 45, 46] (Fig. 3).  
NF-κB can additionally be activated by another pathway, known as “the alternative pathway”, which has been 
classified according to the complex structure of NF-κB [35, 47]. The alternative pathway is, however, activated with 
much slower kinetics than the classical pathway [48]: The alternative NF-κB pathway is linked to the adaptive immune 
system, and it is involved in the development of lymphoid organs by regulating the generation of B and T lymphocytes 
[35]. The alternative pathway is activated by a small number of stimuli, including lymphotoxins (α and β), B cell 
activating factor (BAFF), receptor activator of nuclear factor kappa-B ligand (RANKL) as well as NOD2 [35, 48, 49]. 
The alternative pathway induces NF-κB inducing kinase (NIK) instead of NEMO to phosphorylate and activate the IKK 
complex, which facilitates induction of NF-κB dimers [34, 35]. The alternative pathway is a prerequisite for the 
development of secondary lymphoid tissues. Thus, mice with defects in the alternative pathway signaling are often 
associated with absence of lymph nodes, and a lack of specific lymphoid organization in spleen and thymus [50].       
In IBD research, three independent gene variants of NOD2 exist, a frame-shift mutation (c3020insC (SNP13)) 
and two missense mutations (R702W (SNP8); G908R (SNP12)). Further, some rare variants have been associated with 
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susceptibility to CD [6]. The frame-shift mutation results in an incompetent truncated NOD2 protein [7]. The NOD2 
gene variants cause a reduced response to MDP by generating a loss-of-function phenotype [51]. Thus, PBMCs from 
CD patients with the frame-shift mutation (c3020insC) express reduced levels of pro-inflammatory cytokines, e.g. TNF, 
IL-6 and IL-8 in response to MDP [15, 52, 53]. 
In addition to activation of the NF-κB-mediated pathway, NOD2 stimulation further results in the activation of 
the MAPKs: p38, JNK, and extracellular signal-regulated kinase (ERK); which are intracellular serine/threonine 
specific kinases involved in activation of multiple cellular processes, including cell growth, proliferation, 
differentiation, migration, inflammation and survival [54-58].   
The MDP-NOD2 pathway and T helper cell regulation 
During the last decade a number of hypotheses have discussed the regulatory immunological role of the NOD2-
mutations in skewing Th differentiation. One of these hypotheses claims, that MDP NOD2-activation results in a down-
modulation of TLR2-mediated Th1 responses, in which antigen-presenting cells (APCs) from Nod2-deficient mice exert 
increased amount of IL-12 supporting Th1 inflammatory responses [59]. This hypothesis is supported by observations 
that administration of MDP protects mice from acute experimental colitis [60, 61]. A second hypothesis suggests that 
defects in NOD2 signaling polarize the adoptive immune system towards the Th1/Th17-type, resulting in excessive 
Th1/Th17 cell-mediated inflammation, in which Th1 and Th17 cells are enriched at the inflamed gut together with 
increased levels of pro-inflammatory cytokines [62, 63]. In addition to the previous hypotheses, other studies indicate 
that activation of NOD2 signaling enhances the Th17 polarization. Thus, stimulation of human dendritic cells (DCs) 
with MDP has been shown to enhance NOD2-mediated production of IL-1β and IL-23 which in turn promotes IL-17 
production by memory Th17 cells [64]. Moreover, a recently study reported by Geddes et al. [65] suggests a specific 
role for NOD2 in the early innate response. The authors used a mouse model in identifying an early NOD2-dependent 
Th17 response restricted to the acute phase of infections after treatment with pathogens, including Salmonella 
Typhimurium and Citrobacter rodentium. NOD2 expression by myeloid and somatic cells was a crucial factor in 
recognition of pathogens and thereby for a functional early Th17 response [65]. Further, impaired acute Th17 responses 
in Nod2 knockout mice were associated with unaffected colonic colonization and diminished colonic inflammation at 
early stages, which is in contrast to an enhanced tissue destruction and increased bacterial translocation later in the 
course of the disease, indicating a protective role of the acute Th17 response in infection control [65]. However, 
treatment with human anti-IL-17A monoclonal antibodies has been revealed to be without any clinical effects in CD 
[66]. 
NOD2 seems also to be involved in immune regulatory pathways for maintaining the Th1/Th2/Th17 immune 
balance. For instance, mutations of NOD2 lead to an inhibited IL-10 expression, which is assumed to suppress Th1 cells 
[53, 67]. NOD2 mutations suppress transcription of human IL-10 by inhibitory activity of the nuclear ribonucleoprotein 
hnRNP-A1; a nucleocytoplasmic shuttling heterogeneous nuclear ribonucleoprotein that accompanies eukaryotic 
mRNAs from the active site of transcription to that of translation [67]. Further, human peripheral blood mononuclear 
cells (PBMCs) with the 3020insC frame shift NOD2 mutation have an impaired production of the anti-inflammatory 
cytokine, IL-10 [53, 67]. Based on the observation that IL-10 knockout mice develop colitis, and that loss of function 
mutations in the IL-10 receptor gene leads to early onset of CD in humans, this finding adds another aspect to the 
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importance of NOD2 for balancing various immune responses [68, 69]. Another hypothesis is based on observations 
where NOD2 is found to have a reciprocal interaction with MAPK-kinase transforming growth factor (TGF)-β-
activated kinase 1; TAK1 [70]. NOD2 inhibits TAK1-induced activation of NF-κB [70], and TAK1 gene silencing 
decreases the frequency of Th1 and Th17 cells [71]. This indicates that a loss-of-function phenotype of NOD2-
mutations can lead to an increased TAK1-mediated Th17 cell activation. Recently, short non-coding RNAs, known as 
microRNAs (miRNAs), were profiled in DCs from patients with CD-associated mutations of NOD2, and a down-
regulation in two miRNA clusters was revealed. Interestingly, these clusters were suggested  to regulate a critical 
component of the Th1/ Th17 immune response [72].  
 The dysregulation of the immune balance in Th1/Th2/Th17 is further considered to be of importance for a 
defective Th2 immune response. Magalhaes et al. [73] showed that MDP activation of the NOD2-mediated pathway in 
DCs is insufficient to initiate Th2 immunity in absence of stromal-derived mediators, such as thymic stromal 
lymphopoientin (TSLP). TSLP is thought to promote Th2 immunity by an up-regulation of the expression of OX40 
ligand (OX40L), which is a transmembrane protein expressed by APCs to recognize OX40, a receptor expressed by T 
cells [74, 75]. Magalhaes et al. found that NOD2 stimulation induced the up-regulation of OX40L expression on DCs. 
Moreover, OX40 deficient mice had diminished capabilities in generating NOD2-drived Th2 immunity [73]. 
 T-regulatory Foxp3+ cells are important for the homeostasis of the intestinal immune response, and a lack of T 
regulatory cells has been associated with development of experimental colitis [76]. The dynamic of T-regulatory Foxp3+ 
cells in IBD is still incompletely understood. Several studies have revealed an increased number of mucosal T 
regulatory cells in active CD [77, 78]. On the other hand, the number of T-regulatory Foxp3+ cells has been found to be 
increased in the colonic lamina propria of children with CD treated with anti-TNF-α compared with both CD receiving 
conventional therapy and non-IBD controls patients with active CD [79]. Moreover, the number of T-regulator cells has 
also been reported to be higher in inflamed IBD mucosa than the peripheral blood [80]. It is therefore of interest, that 
the MDP-NOD2 pathway seems to be necessary for survival signaling in T-regulatory Foxp3+ cells [81]. Further, T-
regulatory Foxp3+ cells from CD patients with disease associated gene variants of NOD2 were more susceptible to cell 
death than wild type NOD2 T-regulatory Foxp3+ cells, and the number of T-regulatory Foxp3+ cells were substantially 
decreased in NOD2 mutated patients [81]. The MDP-NOD2 pathway might therefore be crucial for the mucosal 
immune homeostasis as well. 
 MDP has been used as vaccine adjuvant, suggesting that MDP additionally stimulates B-cell adaptive immunity 
[82]. Taken together, these observations reflect the impact of the NOD2 signaling pathway in the dysregulation of 
adaptive responses related to the CD pathogenesis, although further clarification of the pathways involved is needed.          
The MDP-NOD2 pathway in mucosal immunity 
In the mucosal immunity, IECs provide a physical barrier with elemental signal-transduction functions in the 
maintenance of gut homeostasis. IECs consists of a number of epithelial cell types including Paneth cells [83]. The loss-
of-function phenotype of NOD2-mutations has been linked to deficiencies of the epithelial-barrier function, which 
promotes the intestinal bacterial flora invasion and inflammation into the intestinal walls [84]. In Paneth cells, the 
expression levels of NOD2 increases in response to the intestinal bacteria [85, 86]. MDP stimulation of Paneth cells 
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leads to a NF-κB dependent expression and secretion of α-defensins, i.e. anti-microbial peptides, into the intestinal 
lumen [87-90]. Thus, α-defensins levels in CD patients with NOD2 mutations are markedly reduced [91]. This 
reduction of α-defensins is consistent with activated intracytoplasmic digestion (i.e. crinophagy) of the secretory 
granules in CD Paneth cells [92]. In addition, Nod2 knockout mice have been reported to possess a reduced mRNA 
expression of Paneth cell-derived α-defensins. These mice have an impaired intestinal mucosal homeostasis reflected in 
a reduced intestinal bacterial clearance, and an increased bacterial load of the terminal ileum [93, 94].  
 In addition, an abnormal MDP-NOD2 pathway has been associated with intestinal disorders and higher bacterial 
translocation. Thus, MDP stimulation of PBMCs from healthy individuals results in a 2-3-fold enhancement of TLR9 
agonist stimulation of PBMC production of TNF-α and IL-8, whereas such an enhancement is not seen in PBMCs from 
CD patients bearing NOD2 mutations [95], suggesting that the synergistic cytokine response between NOD2 and TLR9 
might have a role in maintaining intestinal homeostasis. Moreover, it was recently found that MDP stimulation of 
murine colorectal epithelial cell lines leads to enhanced TLR2 response in the shape of significantly increased 
expression levels of chemokines, cytokines and tight junction molecules, e.g. claudin-3 and claudin-4 which are 
typically expressed from IECs in the colon to improve the barrier function [96]. Further, the NOD2 genotype has been 
evidenced to influence the bacterial translocation in CD patients due to the fact, that the intestinal endotoxin 
accumulation in heterozygous SNP8 and SNP13 is stronger than in homozygos SNP12 patients and WT patients [97]. 
In addition, Nod2 knockout mice are characterized by significantly higher tissue-associated intestinal bacterial levels 
[93, 94, 98]. Nod2 knockout mice suffered from an impaired bacterial clearance after exposing with pathogens, e.g. 
Listeria monocytogenes, Citrobacter rodentium, Salomonella and Mycobacterium tuberculosis [99-102]. The increased 
bacterial colonization indicates a crucial role for NOD2 in the bacterial clearance. In a recent study, inhibition of NOD2 
using carbamoyl phosphate synthetase/aspartate transcarbamylase/dihydroorotase (CAD) (a newly discovered NOD2-
interacting protein), leads to a dramatic decrease in the clearance of Salmonella [103]. Thus, NOD2 mutations may play 
an essential role in the maintenance of intestinal homeostasis, and the results indicate that an impaired NOD2-mediated 
bacterial clearance might lead to accumulation of mucosal microbiota and secretion of higher levels of pro-
inflammatory cytokines.  
In mucosal immunity, innate lymphoid cell (ILC) populations, which are newly defined innate immune cells, 
have been shown to regulate the epithelial cell responses and maintaining intestinal homeostasis [104]. ILCs constitute 
of both well-established and recently identified T-cell populations and can be grouped into three major groups 
depending on specific transcription factors for their development and function: Group 1 ILCs depends on expression of 
T-bet (T-box expressed in T cells); Group 2 ILCs relay typically on expression of GATA3 (T-cell differentiation is the 
transcription factor GATA-binding protein 3); and Group 3 ILCs which require the expression of RORγt (retinoid-
related orphan receptor γ) [104, 105]. Although only few studies have investigated the MDP signaling in ILCs, the 
presence of this pathway might be involved in the developmental and functional characteristics of ILCs. For instance 
Natural Killer (NK) cells, which belong to Group 1 ILCs and attend in the gut homeostasis by responding to 
commensally enteric bacteria through the innate immune system and cytolytic activity, express high levels of NOD2 
[106], and MDP treatment of these cells leads directly to cell activation through the NOD2-mediated pathway [107]. In 
addition, MDP can also be sensed by TLR2 (described below) [108, 109] which is expressed on RORγt+ ILCs [110].  
Therefore, MDP might have an indirectly influence on ILCs through modulation of other cellular components of the 
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innate immunity. As previously mentioned, DCs stimulated with MDP express high levels of IL-23 and IL-1β [64], 
cytokines that can induce production of IL-22 from RORγt+ ILCs [111, 112]. IL-22 has been reported to ameliorate 
intestinal inflammation in a murine model of experimental colitis [113], and bolster intestinal epithelial barrier function 
by upregulation of antimicrobial peptides [114]. Overall, additional studies are, however, required to clarify the MDP 
signaling and its influence on ILCs responses. 
The MDP-NOD2 pathway and autophagy 
The MDP-NOD2 signaling pathway might be a potential regulatory target for other upstream and downstream genes. 
An interesting illustration of such genes is the autophagy-related protein, 16-like 1 (ATG16L1), which has a key role in 
the process of cellular protein turnover as well as in handling the intracellular bacteria [90, 115]. The prevalence of 
ATG16L1 polymorphism is high, as it exists in around 50% of the European population; however, the loss-of-function 
mutations in ATG16L1 are associated to CD in form of a two-fold increased susceptibility [116-118]. Moreover, NOD2 
is linked to ATG16L1 in the autophagy pathway, and is of importance for the recruitment of ATG16L1 at the site of 
bacterial entry [119]. The link between NOD2 and ATG16L1 was shown by LPS and MDP stimulation of GFP-LC3–
transduced bone marrow–derived macrophages (BMDMs), a cell population expressing functional Nod2: The MDP-
treated, but not LPS-treated, BMDMs showed an activated autophagy in wild-type macrophages, whereas macrophages 
isolated from Nod2-deficent mice did not activate this pathway [119].  
 Taken together these observations indicate that the MPD-NOD2 signaling pathway induces the innate immunity 
at multiple levels, thereby linking important aspects of the pathogenesis of CD to disturbances of the innate immune 
system. Therefore, the normalization of this signaling pathway may normalize the intestinal immunological homeostasis 
in subsets of CD patients with an impaired MDP signaling.   
Cross-talk between NOD2 and other innate pathways 
MDP sensing is not NOD2-restricted. Beyond the ability to activate NOD2-mediated signaling pathways, MDP can 
interact and signal through TLR2 [108, 109] . TLR2 recognizes MDP and activates NEMO-NF-κB pathway through 
two independently upstream signaling pathways [120]. Further, TLR2 triggers the association with myeloid 
differentiation primary-response protein 88 (MyD88), which subsequently can signal either through tumor-necrosis-
factor-receptor-associated factor 6 (TRAF6), or by binding to receptor-interacting serine/threonine kinase (RICK) 
activating pathways similar to those involved in NOD2-signaling [42, 121-123]. Activation of TLR2 also facilitates 
induction of MAPKs signaling pathways [120, 124-126] (Fig. 4). In vitro data on MDP stimulation of splenic 
macrophages isolated from Nod2-deficient mice has shown an excessive NF-κB dependent IL-12 production, pointing 
to a possible NOD2-negative-regulatory role of the TLR2-mediated Th1 response, whereas the expression levels of 
other inflammatory cytokines produced by TLR2-signaling, such as TNF-α and IL-10, were unaffected [59]. In contrast, 
MDP stimulation of NOD2 and TLRs, including TLR2 in human PBMCs, leads to a positive synergistic effect, while 
MDP stimulation of mutant NOD2 cells shows a lack of this immunological response, which results in an impaired NF-
κB signaling pathway [52, 95]. This immunological response is, however, detrimental to the suggested pathogenesis of 
CD with elevated levels of NF-κB activation-dependent Th1 cytokines [127-129]. However, the effect of NOD2-
activation on TLR2-mediated cytokine response has in another study been found to depend on the MDP activation dose 
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and the NOD2-genotype: Stimulation of NOD2-mutant monocytes with low doses of MDP results in a significant 
increase in the TNF-α production, as opposed to a down-regulated response at higher MDP doses. However, when 
monocytes isolated from NOD2-deficient patients are stimulated with high-dose MDP, divergent dynamics are revealed 
as the response of down-regulation lacks [130].  
In addition to the previous mentioned NOD2-interaction, it has further been reported that NOD2 plays a major 
role in activation of innate immune antiviral responses. Sabbah et al. [131] reported that NOD2 is involved in induction 
of antiviral cytokines, including IFN-β, in response to external viral stimuli such as single-stranded RNA (ssRNA) and 
respiratory syncytial virus (RSV). The authors found that the activation mechanism requires NBD and LRR domain of 
NOD2 interaction with the mitochondrial antiviral signaling (MAVS) protein. The NOD2-MAVS protein complex 
facilitates the NOD2-mediated response by activating interferon-regulatory factor 3 (IRF3), which subsequently 
translocates to the nucleus and activates production of cytokines such as IFNs [132]. Additionally, recent studies have 
revealed a synergistic proinflammatory cytokine response in human PBMCs stimulated with RSV followed by MDP 
stimulation. Interestingly, this synergic response is absent in PBMCs isolated from CD patients homozygous for the 
3020insC mutation in the NOD2 gene [133]. These results suggest a critical role of NOD2 in this synergy and add an 
interesting aspect in how the loss of function mutations in NOD2 can eliminate essential immune responses. 
The inflammasome-mediated pathway 
Another outcome of MDP recognizing by PRRs is the formation of inflammasomes, i.e. multiprotein complexes, which 
are involved in the conversion of pro-caspase-1 to casapase-1 through a CARD-CARD interaction. Active caspase 1 
leads to cleavage of pro-inflammatory cytokines, such as pro-IL-1β and pro-IL-18, allowing more secretion of mature 
IL-1β and IL-18 [134, 135] (Fig. 5). Recently, Meinzer et al.[136] showed that Yersinia pseudotuberculosis induces an 
intestinal barrier dysfunction by subverting signaling of Nod2. They reported that acetylation of RICK and TAK1 
kinases resulted in a reduced affinity for Nod2. Thus the free Nod2 interacts with and activates caspase-1 resulting in 
increased levels of IL-1β, which contributes to the induction of intestinal barrier dysfunction in Peyer's patches [136]. 
The NLR family encodes a key component in the innate immunity by microbe recognizing, and the activation of 
response signaling pathways. One of these pivotal pathways is the NLR control of inflammatory caspases, such as 
caspase-1 via formation of inflammasomes [137-139]. Four inflammasomes have been identified and named after the 
PRR that regulates their activity: NLRP1, NLRP3, NLRC4 and AIM2 (absent in melanoma 2), an intracellular DNA 
receptor [137, 140]. Three of them include PRRs from the NLR family: NLRP1, NLRP3 and NLRC4, which are 
composed of a C-terminal leucine-rich repeat domain, a central nucleotide-binding domain, and of an N-terminal 
effector domain, CARD or pyrin domain (PYD) (Fig. 5) [141]. NLRPs contain PYD, while CARD mediates 
downstream protein-protein interaction in NLRCs [142]. Recently, AIM2, a non-NLR family member belonging to the 
interferon-inducible HIN-200 protein family, was identified as a cytosolic double-stranded DNA (dsDNA) sensor 
facilitating formation of the AIM2 inflammasome. The AIM2 PYD interacts with adaptor protein apoptosis-associated 
speck-like protein (ASC) to recruit caspase-1 via its CARD and results in caspase-1-dependent IL-1β induction [143-
146].  
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The initial description of the inflammasome was established on observations showing that formation of the 
human NLRP1 inflammasome was required for activation of the pro-inflammatory protease, caspase-1[137, 147]. MDP 
has been identified as inducer for the NLRP1 inflammasome and IL-1β secretion, in which NOD2/NLRP1 complexes 
are believed to mediate the process of caspase-1-dependent-IL-1β secretion [148], although no evident MDP-NLRP1-
interacting has been found [149]. In addition, MDP was found to induce the activation of NLRP3 inflammasome [22, 
150]. The activation mechanism of the NLRP3 inflammasome requires induction of NLRP3 expression mediated by 
NF-κB [150-152]. A recent study revealed that NLRP3 variants contribute to the CD susceptibility, indicating an 
important interference of the inflammasome in the pathogenesis of CD [153]. The gain-of-function mutation in NLRP3 
leads to elevated levels of IL-1β produced by human monocytes THP-1 cells [154]. This finding might also be 
associated with other severe inflammatory disorders, e.g. Muckle-Wells syndrome, familial cold autoinflammatory 
syndrome and neonatal-onset multisystem inflammatory [155, 156].   
Other MDP-dependent pathways and clinical implications 
Decreased bone mineral density (BMD) is a common extraintestinal complication in IBD [157-159]. The balance 
between bone resorption and formation, i.e. the process of bone remodeling, is tightly regulated by osteoclasts and 
osteoblasts, respectively [160]. In recent studies, MDP has been found to contribute synergistically to the enhancement 
of osteoclasts formation through elevated NOD2-dependent expression of RANKL osteoblasts [161]. These 
observations suggest that MDP might play a key role in osteoclastic bone resorption in inflammatory bone diseases.  
Moreover, MDP can elicit divergent biological effects dependent on the activated biological switch. For instance 
a number of apoptotic pathways are induced by the MDP-dependent pathway, such as the calreticulin (CRT) and the 
ASC-mediated pathway [162, 163]. MDP activation of CRT, an endoplasmic reticulum Ca2+ binding chaperone with 
multiple functions [164], results in the induction of a conformational change of TNFR1-associated death domain protein 
(TRADD) or Fas associated death domain protein (FADD), which subsequently activates caspase-8 and thereby cell 
death in cell lines such as rabbit kidney epithelial cells and Hela cells [163, 165]. Normalization of this apoptotic 
pathway might imply a promising treatment procedure for IBD. For instance repressing of FADD in mouse model of 
acute experimental colitis leads to a modulation of TNF-mediated intestinal epithelial apoptosis [166]. 
In addition to its role as an adaptor protein linking NLR proteins with caspases, the ASC protein interacts with 
MDP and activates caspase-8-mediated apoptosis [162]. Previously, ASC has been shown to be involved in the 
chemosensitivity of cancer cells [167], and the ASC-mediated apoptosis might thus be a potential target in oncology. 
Concluding remarks 
In combination with genetic and environmental factors, the luminal bacterial flora plays a pivotal role in the initiation 
and perpetuation of IBD. An analysis of published research shows that MDP induces a wide range of biological effects, 
and further, that impairment of MDP related pathways might contribute to the inflammatory process in CD. Thus, MDP 
can activate divergent extra- and intracellular PRRs and utilize several strategies for intracellular delivery. NOD2 is a 
well-known innate cytosolic receptor that senses the intracellular MDP. MDP-NOD2 interaction has been shown to 
activate NF-κB-dependent pro-inflammatory and antibacterial responses. Mutations in NOD2 are associated with an 
early onset and a more complicated clinical course of CD including fibrostenosis and fistulization, but the functional 
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link between these mutations and CD has not been entirely elucidated. There are several possible mechanisms for a 
dysfunctional role of NOD2 in CD susceptibility. It has been suggested that defects in NOD2 signaling polarize the 
adoptive immune towards Th1/Th17-type, which leads to an excessive Th1/Th17 cell-mediated inflammation. In 
addition, NOD2 signaling has been reported as both a negative and a positive regulator of TLR responses. A NOD2 
mutation can drive Th1 immune response by negative regulation of TLR2, whereas NOD2 can also provide a 
synergistic effect with TLR9 in maintaining intestinal homeostasis. An impaired NOD2 interaction with ATG16L1, and 
thereby impaired autophagy causing defect bacterial handling, is another likely mechanism of CD associated dysbiosis.   
Recent studies have expanded the induction ability of MDP beyond interaction with NOD2. Indeed, MDP has 
been shown to interact with inflammasomes, through NLRP1 and NLRP3, and to induce production of the pro-
inflammatory cytokines belonging to the IL-1 family of cytokines. Further, NOD2 signaling might be impaired even in 
CD patients with the wild-type NOD2 gene variant, suggesting that epigenetic changes and alternations downstream to 
NOD2 could play a key role in the bacteria host interaction in CD [168]. The understanding of how interaction between 
MDP producing bacteria and the innate immune system contributes to the pathogenesis of CD therefore relies on a 
better understanding of how shutting down of one part of the MDP response (e.g. by defect NOD2 signaling), poses 
imbalances towards other parts of the NOD2 response (e.g. non-NOD2 dependent signaling). Forcing or enhancing 
signaling through these pathways by stimulation with small molecules could in this way downgrade the imbalance and 
normalize the innate immune response, and thereby reduce the inflammatory burden in CD, as it has been observed in 
experimental colitis [60, 169].  
In this review several findings related to the molecular mechanisms of intracellular delivery of MDP and its 
biological effect in the CD pathogenesis have been highlighted. Furthermore, the cross-talk between NOD2 and other 
innate signaling pathways of relevance to disease pathogenesis have been described, as well as the role of MDP in the 
inflammasome-mediated and various other pathways (e.g. NOD2 and TLR2). Altogether, these observations raise 
questions on the responsive roles of MDP for the innate immunity and CD pathogenesis, and it is assumed that 
clarification of the impact of MDP could possess major implications of importance for future treatment strategies for 
CD.        
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Legends to figures 
 
Figure 1. Mechanisms of MDP intracellular delivery. (A) Extracellular MDP can permeabilize the host cell through 
membrane receptors such as hPepT1 and Pennexin-1. (B) Extracellular MDP can also be transported into the host cell 
by clathrin- and dynamin-dependent endocytic pathways. (C) Moreover, MDP can be derived from bacteria by the 
intracellular phagocytic cleavage. (D) Finally, MDP can additionally be released to the cytosol through autolysis of 
internalized of invasive bacteria. 
 
Figure 2. Structure of NOD2. The structure of NOD2 consists of two N-terminal caspase recruitment domains 
(CARDs) which mediate protein-protein interactions, a centrally located nucleotide-binding domain (NBD) which 
mediates protein self-oligomerization required for activation, and C-terminal of site of ligand binding, i.e. leucine-rich 
repeats (LRRs). 
 
Figure 3. Signaling pathway of NOD2. Recognition of MDP through LRRs domain activates NOD2 and causes a 
conformational change, allowing a CARD-CARD interaction between NOD2 and RIP2; receptor-interacting protein 2. 
The activation of RIP2 upon binding with NOD2 results in polyubiquitination (ub) of NEMO; NF-κB essential modifier 
(or IKKγ; inhibitor of IκB kinase γ), which is found in complex with IKKα and IKKβ. This is followed by the 
phosphorylation of IKKβ as well as the phosphorylation of IκB; inhibitor of NF-κB, and the release of NF-κB. NF-κB 
can subsequently translocate into the nucleus and promote transcription of many pro-inflammatory and anti-
inflammatory cytokines, including interleukin-1 (IL-1), IL-2, IL-6, IL-8, IL-12, and TNF-α.  
 
Figure 4. TLR2 activation with MDP. Binding of MDP to TLR2 starts a signaling cascade initiated by activation of 
MyD88; myeloid differentiation primary-response protein 88. This cascade activates tumor-necrosis-factor-receptor-
associated factor 6; TRAF6, or by binding to receptor-interacting serine/threonine kinase; RICK, resulting in induction 
of MAPK- and NF-κB-mediated responses, such as inflammation and Th1/Th2 activation. 
 
Figure 5. MDP activation of pro-inflammatory cytokines through inflammasome-mediated pathway. The 
prototype structures of NLRP1, NLRP3 and NLRC4 consist of the following major interaction domains: The ligand 
sensing leucine - rich repeats (LRR), NACHT or the oligomerization domain, pyrin domain (PYD) or caspase 
recruitment domain (CARD), and function to find domain (FIIND). MDP interaction with these NLRs leads to the 
formation of inflammasomes, which are able to convert pro-inflammatory cytokines into their biologically active form.  
